TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T‐CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST‐HOC ANALYSIS OF THE MAVORIC STUDY. (12th June 2019) - Kim, Y.H.; Ortiz‐Romero, P.L.; Pro, B.; Sokol, L.; Scarisbrick, J.; Musiek, A.; Vermeer, M.; Dummer, R.; Halwani, A.; Fierro, M.; Moriya, J.; Leoni, M.; et al.